Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab Conditioning for CLL/Richter's Allo-SCT
NCT03153514Phase 2Terminated
- Sponsor
- German CLL Study Group
- Start
- Nov 2017
- Primary completion
- May 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab in chronic lymphocytic leukemia (CLL) and Richter's transformation (RT), sponsored by German CLL Study Group. Primary endpoint: Progressive Disease-free rate. Started Nov 2017; status: terminated.
02
Drugs
obinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)Richter's transformation (RT)
Beyond the preview
Go deeper on NCT03153514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03153514.